Trends in price, spending, and utilization of omalizumab among Medicare beneficiaries

Lillian W Dattilo,Vinay K. Rathi,Rodney J. Schlosser,Zachary M. Soler,George A. Scangas,Alan D. Workman,Stacey T. Gray

International Forum of Allergy & Rhinology（2023）

引用 0|浏览1

暂无评分

摘要

Key Points Between January 2005 and January 2023, the average selling price of omalizumab increased by nearly 60%. Between 2016 and 2021, Medicare Part B and D spending on omalizumab totaled over $3.7 billion. Between 2016 and 2021, Medicare Part B and D utilization of omalizumab increased by approximately 30%.

查看译文

关键词

omalizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要